Corbus Pharmaceuticals

Company snapshot

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Corbus Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  Ultragenyx UK

  TA overlap score 40

• Peer + 0 momentum

  Lakefront Biotherapeutics NV

  TA overlap score 39.8

• Peer + 0 momentum

  WINDTREE THERAPEUTICS INC

  TA overlap score 23

• Peer + 0 momentum

  CytomX Therapeutics

  TA overlap score 21.6

• Peer + 0 momentum

  PURPLE BIOTECH

  TA overlap score 20.6

Recent activity

Latest pipeline, patent, and corporate events for Corbus Pharmaceuticals.

1. Jun 5, 2026 Clinical update

   JBT-101 — Phase 2

2. Jun 5, 2026 Clinical update

   CRB-601 monoclonal antibody — Phase 2

3. May 26, 2026 Clinical update

   A Clinical Trial for Patients with Advanced Cancers — Phase 2

4. May 23, 2026 Clinical update

   Lenabasum 20 mg — Phase 3

5. May 23, 2026 Clinical update

   Lenabasum 5 mg — Phase 3

View all clinical trial activity →

• What is Corbus Pharmaceuticals?

  Corbus Pharmaceuticals is a pharma organization headquartered in Norwood, USA. It trades on NYSE under ticker CRBP. Primary therapeutic focus areas include Dermatomyositis, Diffuse Cutaneous Systemic Sclerosis, Cystic Fibrosis, Advanced Solid tumour, Solid Tumor. NovaPharmaNews l

• Is Corbus Pharmaceuticals publicly traded?

  Yes. Corbus Pharmaceuticals is listed with ticker CRBP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Corbus Pharmaceuticals develop or market?

  We link 3 drug profile(s) where Corbus Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/corbus-pharmaceuticals-holdings#company-drugs.

• What are the latest developments for Corbus Pharmaceuticals?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Corbus Pharmaceuticals focus on?

  Corbus Pharmaceuticals focuses on Dermatomyositis, Diffuse Cutaneous Systemic Sclerosis, Cystic Fibrosis based on our analysis of their pipeline programs and drug development activities.